Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy By Ogkologos - February 19, 2026 174 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Young Man’s “Water You Can Eat” Invention for His Grandma with... July 8, 2020 Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in... April 23, 2026 FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway... July 15, 2026 EMA Adopts a Positive Opinion for a New Indication for Pembrolizumab August 24, 2023 Load more HOT NEWS Foodie Friday: Butternut Squash Macaroni Casserole 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to... EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib
